Atorvastatin/Hydrochlorothiazide/Aspirin/Enalapril

阿托伐他汀/氢氯噻嗪/阿司匹林/依那普利

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAtorvastatin/Hydrochlorothiazide/Aspirin/Enalapril
Drug Alias Nameacetylsalicylic acid + hydrochlorothiazide + enalapril + atorvastatin氢氯噻嗪/阿司匹林/依那普利/阿托伐他汀Aspirin/Hydrochlorothiazide/Enalapril/Atorvastatin依那普利/阿托伐他汀/氢氯噻嗪/阿司匹林Hydrochlorothiazide/Enalapril/Atorvastatin/Aspirin +[10] 
ClassificationSmall molecules
Mechanisms of ActionCyclooxygenases inhibitorsHMG-CoA reductase inhibitorsThiazide-sensitive sodium-chloride cotransporter inhibitors +[4] 
TargetsThiazide-sensitive sodium-chloride cotransporterAngiotensin-converting enzymeHMG-CoA reductase +[4] 
Therapy Area/IndicationsHyperlipidemiasHypertensionHeart Diseases +[4] 
Global Approved IndicationsCardiovascular Diseases
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIran
Original Approved Date2018/02/01
Country/TerritoryIran
CombinationsYes HydrochlorothiazideEnalapril MaleateAspirin
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlborz Darou Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesAlborz Darou Pharmaceutical
Inactive CompaniesTehran University Of Medical Sciences
Active IndicationsCardiovascular Diseases
Inactive IndicationsHyperlipidemiasHypertensionHeart Diseases

Other Information

ATC CodeC03AX01
Related LinksN/A